Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

被引：42

作者：

Coll, Blai ^{[1
]}

Aragones, Gerard

Parra, Sandra

Alonso-Villaverde, Carlos

Masana, Lluis

机构：

[1] Hosp Univ St Joan, Ctr Rec Biomed, Reus, Spain

[2] Hosp Univ St Joan, Med Interna Serv, Reus, Spain

来源：

AIDS | 2006年 / 20卷 / 12期

关键词：

D O I：

10.1097/01.aids.0000238418.43937.3b

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.

引用

页码：1675 / 1677

页数：3

共 15 条

[1] Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial [J].

Ballantyne, CM ;

Houri, J ;

Notarbartolo, A ;

Melani, L ;

Lipka, LJ ;

Suresh, R ;

Sun, S ;

LeBeaut, AP ;

Sager, PT ;

Veltri, EP .

CIRCULATION, 2003, 107 (19) :2409-2415

[2] Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: Comparison of efficacy and interaction with indinavir [J].

Benesic, A ;

Zilly, M ;

Kluge, F ;

Weissbrich, B ;

Winzer, R ;

Klinker, H ;

Langmann, P .

INFECTION, 2004, 32 (04) :229-233

[3] Endothelial dysfunction - A marker of atherosclerotic risk [J].

Bonetti, PO ;

Lerman, LO ;

Lerman, A .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (02) :168-175

[4] Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia [J].

Bonetti, PO ;

Pumper, GM ;

Higano, ST ;

Holmes, DR ;

Kuvin, JT ;

Lerman, A .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) :2137-2141

[5]

Chuck Susan K, 2002, Expert Opin Drug Saf, V1, P5

[6] HIV infection, HAART, and endothelial adhesion molecules: current perspectives [J].

Donati, KD ;

Rabagliati, R ;

Iacoviello, L ;

Cauda, R .

LANCET INFECTIOUS DISEASES, 2004, 4 (04) :213-222

[7]

Doser Nicole, 2002, AIDS (Hagerstown), V16, P1982, DOI 10.1097/00002030-200209270-00024

[8] Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 [J].

Fichtenbaum, CJ ;

Gerber, JG ;

Rosenkranz, SL ;

Segal, Y ;

Aberg, JA ;

Blaschke, T ;

Alston, B ;

Fang, F ;

Kosel, B ;

Aweeka, F .

AIDS, 2002, 16 (04) :569-577

[9] Combination antiretroviral therapy and the risk of myocardial infarction [J].

Friis-Moller, N ;

Sabin, CA ;

Weber, R ;

Monforte, AD ;

El-Sadr, WM ;

Reiss, P ;

Thiébaut, R ;

Morfeldt, L ;

De Wit, S ;

Pradier, C ;

Calvo, G ;

Law, MG ;

Kirk, O ;

Phillips, AN ;

Lundgren, JD ;

Weber, R ;

Monteforte, AD ;

Bartsch, G ;

Reiss, P ;

Dabis, F ;

Morfeldt, L ;

De Wit, S ;

Pradier, C ;

Calvo, G ;

Law, MG ;

Kirk, O ;

Phillips, AN ;

Houyez, F ;

Loeliger, E ;

Tressler, R ;

Weller, I ;

Friis-Moller, N ;

Sabin, CA ;

Sjol, A ;

Lundgren, JD ;

Sawitz, A ;

Rickenbach, M ;

Pezzotti, P ;

Krum, E ;

Meester, R ;

Lavignolle, V ;

Sundström, A ;

Poll, B ;

Fontas, E ;

Torres, F ;

Petoumenos, K ;

Kjær, J ;

Hammer, S ;

Neaton, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003

[10] Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin [J].

Hsyu, PH ;

Schultz-Smith, MD ;

Lillibridge, JH ;

Lewis, RH ;

Kerr, BM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3445-3450

← 1 2 →